Peralta factual exhibit: Q3 2026 financial cash rows

Reconstructed from original issuer/SEC rows; original source:
https://www.sec.gov/Archives/edgar/data/1932393/000193239326000059/gehc-20260930.htm

Nine-month 2026 revenue USD 15,939 million; operating income USD 2,058 million.

Nine-month 2026 net income USD 1,608 million; operating cash USD 1,365 million.

Nine-month 2026 pension contributions USD 243 million; inventory use USD 430 million.

Nine-month 2026 capital additions USD 392 million; acquisitions USD 2,293 million.

Nine-month 2026 dividends USD 48 million; common repurchases USD 300 million.

Research cutoff 2026-11-25. Original filing controls if exhibit transcription differs.

Peralta factual exhibit: Q3 2026 segment rows

Reconstructed from original issuer/SEC rows; original source:
https://www.sec.gov/Archives/edgar/data/1932393/000193239326000059/gehc-20260930.htm

AIS nine-month revenue USD 11,284 million and segment EBIT USD 1,596 million.

PDx nine-month revenue USD 2,458 million and segment EBIT USD 699 million.

PCS nine-month revenue USD 2,171 million and segment EBIT USD 52 million.

Total segment EBIT including Other USD 2,353 million; restructuring USD 92 million.

Acquisition-related intangible amortization USD 169 million, nine months 2026.

Research cutoff 2026-11-25. Original filing controls if exhibit transcription differs.

Peralta factual exhibit: Q3 2026 claims and capital

Reconstructed from original issuer/SEC rows; original source:
https://www.sec.gov/Archives/edgar/data/1932393/000193239326000059/gehc-20260930.htm

September 2026 cash and restricted cash USD 2,854 million.

September 2026 borrowings USD 9,973 million.

September 2026 redeemable minority USD 234 million and other minority USD 17 million.

September 2026 inventories USD 2,628 million versus December 2025 USD 2,234 million.

Nine-month 2026 diluted weighted average shares 455 million.

Peralta factual exhibit: 2025 audited history and 2026 guidance

Reconstructed from original issuer/SEC rows; original source:
https://www.sec.gov/Archives/edgar/data/1932393/000193239326000007/gehc-20251231.htm

2025 revenue USD 20,625 million; operating income USD 2,763 million.

2025 operating cash USD 1,987 million; capital additions USD 482 million.

2025 diluted EPS USD 4.55; diluted weighted shares 458 million.

2026 GEHC guidance adjusted EPS USD 4.95 to 5.05 and FCF at least USD 1.6 billion.

Guidance source https://investor.gehealthcare.com/news-releases/news-release-details/ge-healthcare-report

Research cutoff 2026-11-25. Original filing controls if exhibit transcription differs.

Peralta factual exhibit: Ownership and subsequent filing

Reconstructed from original issuer/SEC rows; original source:
https://www.sec.gov/Archives/edgar/data/1932393/000193239326000021/gehc-20260318.htm

Proxy March 9 2026 Vanguard 52,535,829 shares, 11.5 percent.

Proxy March 9 2026 BlackRock 36,271,390 shares, 7.9 percent.

Nov 5 2026 8-K: Taha Kass-Hout resignation effective December 31, 2026.

8-K source https://www.sec.gov/Archives/edgar/data/1932393/000193239326000063/gehc-20261104.htm